Latest Diagnostic and Treatment Modalities for TTP

AliRaza Ghani

Authors

AliRaza Ghani

Keywords:

atypical hemolytic uremic syndrome, complement factors, thrombotic thrombocytopenic purpura, plasmapharesis, eculizumab

Abstract

TTP is a very uncommon disease which used to have very high mortality and morbidity before the introduction of plasmapharesis and immunosup-pressant therapy. Even after the introduction of these modalities, atypical HUS patients had a very grave prognosis and ultimately led to death in many until the introduction of complement inhibitors like eculizumab which is C5a monoclonal antibody. Additionally differentiating typical HUS versus atypical HUS was very difficult but some work on complement markers can be very fruitful in differentiating them.

Downloads

How to Cite

Latest Diagnostic and Treatment Modalities for TTP. (2014). Global Journal of Medical Research, 14(F3), 11-16. https://medicalresearchjournal.org/index.php/GJMR/article/view/644

Download Citation

References

James George (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. 116(20), 4060-4069.

M Scully, B Hunt, S Benjamin (2012) Guidelines on the diagnosis and management of thrombotic thromb-ocytopenic purpura and other thrombotic microan-giopathies. 158, 323.

Giuseppe Remuzzi, Serafino Garella (1987) HUS and TTP: Variable expression of a single entity. 32(2), 292-308.

Piero Ruggenenti, Marina Noris, Giuseppe Remuzzi (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. 60(3), 831-846.

S Allford, B Hunt, P Rose (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathichaemolyticanaemias. 120, 556.

H Tsai (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. 14, 1072.

Gail Rock, Kenneth Shumak, Noel Buskard, Victor Blanchette, John Kelton, Rama Nair, Robert Spasoff (1991) Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura. 325(6), 393-397.

Sara Vesely, James George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez El-Harake, Gary Raskob (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. 102(1), 60-68.

J Moake (2002) Thrombotic microangiopathies. 347, 589.

J Sadler (2008) Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. 112, 11.

E Amorosi, J Ultmann (1966) Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. 45, 139.

Von Baeyer, H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. 6, 320.

B Wyllie, A Garg, J Macnab, G Rock, W Clark (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. 132(2), 204-209.

Mini Michael, Elizabeth Elliott, Greta Ridley, Elisabeth Hodson, Jonathan Craig (2009) Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. 3595.

Kremer Hovinga, J Vesely, S Terrell, D (2010) Survival and relapse in patients with thrombotic thromboc-ytopenic purpura. 115, 1500.

Samhar Al-Akash, P Almond, Van Savell, Salam Gharaybeh, Cris Hogue (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. 26(4), 613-619.

J Jump Up^ Zuber, Le Quintrec, M Sberro-Soussan, R Loirat, C Frémeaux-Bacchi, V Legendre, C (2011) New insights into postrenal transplant hemolytic uremic syndrome. 7(1), 23-35.

Han-Mou Tsai (2010) Pathophysiology of thrombotic thrombocytopenic purpura. 91(1), 1-19.